CybeRelease: (OTC: AMZB) in Early Negotiations With Major Pharmaceutical Companies
(CybeRelease, April 2, 2007) - Lake Harmony, PA- Amazon Biotech, Inc. (OTC BB: AMZB) (Frankfurt: B2D.F) announced that it has secured the services of Mr. Stanley Fass to negotiate a joint venture agreement between Amazon Biotech and major pharmaceutical companies.
Amazon Biotech has entered in negotiations with major pharmaceutical companies for funding of future studies and marketing of the company’s anti-HIV drug, AMZ0026 which has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Mr. Fass had previously been with Intec Pharma Ltd. as vice president business development where he successfully negotiated a joint venture with Glaxo SmithKline (GSK). He also served as President of Perio Products, Ltd. for 12 years where he successfully negotiated joint venture agreements with Astra Pharmaceuticals, Procter & Gamble, Carter-Wallace, Colgate, Novartis, AL Pharma, IofI in Japan, amongst others.
Dr. Mechael Kanovsky, CEO of Amazon Biotech, said, “The negotiations are in early stages and there is no assurance that any of these negotiations will lead to a joint venture deal. However, we are pleased that a number of large pharmaceutical companies have shown preliminary interest in our phytopharmaceutical drug product.”
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company’s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans, upon funding, to initiate Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. All negotiations that are currently going on with major pharmaceutical companies are in the early stages and may not lead to any agreements or contracts. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
For more information, go to http://biz.yahoo.com/iw/070330/0232802.html
For a Free Newsletter, go to http://www.OTCReporter.com
CybeRelease Gainers are PMC - Sierra, Inc. (Nasdaq: PMCS), Medarex, Inc. (Nasdaq: MEDX), Vivus, Inc. (Nasdaq: VVUS), True Religion Apparel, Inc. (Nasdaq: TRLG), Antigenics Inc. (Nasdaq: AGEN), Genitope Corporation (Nasdaq: GTOP), Sanderson Farms, Inc. (Nasdaq: SAFM) and Favrille, Inc. (Nasdaq: FVRL).
CybeRelease Decliners are TIBCO Software, Inc. (Nasdaq: TIBX), Targeted Genetics Corporation (Nasdaq: TGEN), ICT Group, Inc. (Nasdaq: ICTG), Take-Two Interactive Software, Inc. (Nasdaq: TTWO), Jones Soda Co. (Nasdaq: JSDA), La Jolla Pharmaceutical Company (Nasdaq: LJPC), Bell Microproducts Inc. (Nasdaq: BELM) and USANA Health Sciences Inc. (Nasdaq: USNA.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send No Faxes or Emails.
- Contact Information
- C. P. Barry
- Media Contact
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.